Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Merck & Co. 16.607, AstraZeneca 15.384.
Merck & Co. vs AstraZeneca Net Worth and Market Cap
Merck & Co. (MRK) and AstraZeneca (AZN) are peers in GLP-1. Merck & Co. reported revenue of $16.6B as of Q2 2026, compared with $15.4B for AstraZeneca. Merck & Co. leads on revenue.
Merck & Co.'s gross margin is 73.5% versus 83.6% for AstraZeneca. Merck & Co.'s net margin is -8.0% versus 16.3% for AstraZeneca.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: AstraZeneca +6.4%, Merck & Co. +5.1%.
- AstraZeneca made an operating profit in its latest quarter (20.6% margin); Merck & Co. made an operating loss (-4.1%).
- Merck & Co.'s KPIs on Sterling include Merck Animal Health Livestock vs Companion Animal (Quarterly) and Merck Gardasil China Sales as Printed.
- AstraZeneca's KPIs on Sterling include Alliance Revenue by Partnered Medicine (Quarterly) and AZD5004 + AZD6234 Trial Timeline: Oral GLP-1 + Oral Amylin.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., AstraZeneca.| Metric | Merck & Co. | AstraZeneca |
|---|---|---|
| Market Cap | - | - |
| Revenue | $16.61B | $15.38B |
| Cost of Revenue | $4.39B | $2.52B |
| Gross Profit | $12.21B | $12.86B |
| Operating Income | $-683.00M | $3.16B |
| Net Income | $-1.33B | $2.51B |
| R&D Expense | $9.74B | $4.05B |
| Earnings Per Share | -$0.54 | $1.59 |
| Gross Margin | 73.5% | 83.6% |
| Operating Margin | -4.1% | 20.6% |
| Net Profit Margin | -8.0% | 16.3% |
| Free Cash Flow | $4.48B | $2.13B |
| Cumulative Free Cash Flow | $249.70B | $121.22B |
| Operating Cash Flow | $5.37B | $2.89B |
| Cash & Equivalents | $6.85B | $4.89B |